Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05061134
Title A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (MONETTE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications

skin melanoma

acral lentiginous melanoma

mucosal melanoma

Therapies

Ceralasertib + Durvalumab

Ceralasertib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.